Overview

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Eli Lilly and Company